MD Anderson Cancer Center

UT MD Anderson, GSK collaborate on new approach to cancer immune therapy

Friday, December 7, 2012 02:06 PM

The University of Texas MD Anderson Cancer Center and global healthcare company GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

More... »

Hagop Kantarjian joins Actinium Pharmaceuticals’ clinical advisory board

Wednesday, October 3, 2012 09:39 AM

Actinium Pharmaceuticals (API), a New York-based biopharmaceutical company focused on immunotherapeutics, has appointed Hagop Kantarjian, MD, to the company's clinical advisory board. 

More... »

First MDS consortium to conduct trials and research to improve patient outcomes

Thursday, June 14, 2012 09:23 AM

Taussig Cancer Institute at Cleveland Clinic will participate in an unprecedented, six-institution consortium designed to conduct clinical trials and research to improve outcomes for patients with myelodysplastic syndrome (MDS).

More... »

Goodwin Biotech, MD Anderson collaborate on GMP manufacturing of fusion protein conjugate

Monday, June 4, 2012 09:40 AM

Goodwin Biotechnology (GBI) of Plantation, Fla., and the University of Texas MD Anderson Cancer Center have collaborated on process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator.

More... »

Arrowhead Research acquires Alvos Therapeutics

Wednesday, April 11, 2012 11:12 AM

Arrowhead Research, a nanomedicine company with development programs in RNA therapeutics and obesity, has acquired Alvos Therapeutics (formerly Mercator Therapeutics), the first biopharmaceutical company to use in vivo phage display technology to systematically develop novel cancer drugs.

More... »

Syndax initiates phase I/II study in metastatic breast cancer

Monday, April 9, 2012 04:42 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has initiated a phase I/II study combining its lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... »

BioLife Solutions adds to Scientific Advisory Board

Monday, January 23, 2012 12:32 PM

BioLife Solutions, a developer, manufacturer and marketer of proprietary hypothermic storage and cryopreservation freeze media, has added three key opinion leaders in the biobanking, drug discovery and regenerative medicine markets to its Scientific Advisory Board (SAB).

More... »

Radvanyi joins Genesis Biopharma

Wednesday, July 6, 2011 10:19 AM

Genesis Biopharma, a biotechnology company developing targeted cancer therapies, has named Laszlo Radvanyi, Ph.D., to its Scientific and Medical Advisory Board.

More... »

Baylor Research Institute appoints Yong-Jun Liu as VP, CSO

Friday, April 29, 2011 12:20 PM

Baylor Research Institute (BRI), the research arm of Baylor Health Care System (BHCS), has appointed Yong-Jun Liu, M.D., Ph.D., vice president and chief scientific officer (CSO) for BRI and director of the Baylor Institute for Immunology Research (BIIR).

More... »

Tarix enrolls first patient in TXA127 study

Wednesday, April 27, 2011 02:16 PM

Tarix Pharmaceuticals has enrolled the first patient in a phase I clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. 

More... »